| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a...
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class ...
Cantor Fitzgerald analyst Ross Osborn reiterates Mainz Biomed (NASDAQ:MYNZ) with a Neutral.
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE:
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but al...
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a leader in molecular genetics diagnostic so...
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a leader in molecular genetics diagnostic so...
HC Wainwright & Co. analyst Yi Chen maintains Mainz Biomed (NASDAQ:MYNZ) with a Buy and lowers the price target from $5 ...
Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned indus...
